Supernus' Oxtellar XR Gets 3rd U.S. Patent - Analyst Blog

By
A A A

The U.S. Patent and Trademark Office (USPTO) recently issued a new U.S. patent (Patent No. 8,617,600) to Supernus Pharmaceuticals, Inc. 's ( SUPN ) antiepileptic drug, Oxtellar XR.

The patent, which will not expire before 2027, will protect Oxtellar XR from generic threat. This new patent boosts the existing patent portfolio of Oxtellar XR, which already has two issued patents.

In Feb 2013, Supernus launched Oxtellar XR in the U.S. The company reported meaningful growth in the Oxtellar XR prescriber base in the third quarter of 2013, totaling 7,596, up from 3,648 in the second quarter. Since its launch, more than 1,600 target physicians have prescribed Oxtellar XR. Recognized revenue for Oxtellar XR in the first nine months of 2013 was $1.3 million. Deferred revenues at the end of Sep 2013 were $6.6 million. Supernus expects revenues of $8.5 million for Oxtellar XR in 2013.

Last month, Supernus presented data on Oxtellar XR at the American Epilepsy Society (AES) meeting. During the double-blind PROSPER study on Oxtellar XR, seizure control was maintained. In addition, seizure control improved further during the long-term, open-label, extension study when dosages could be optimized. Oxtellar XR was also well tolerated during long-term maintenance therapy.

Supernus has an agreement with Patheon Inc. for the manufacture, formulation, development and supply of commercial-grade quantities of oxcarbazepine, the active pharmaceutical ingredient in Supernus' Oxtellar XR, in the U.S.

Supernus carries a Zacks Rank #3 (Hold). Other players in the pharma industry, which look attractive at current levels, include Sucampo Pharmaceuticals Inc. ( SCMP ), WuXi PharmaTech (Cayman) Inc. ( WX ) and Forest Laboratories Inc. ( FRX ). All the three stocks carry a Zacks Rank #1 (Strong Buy).



FOREST LABS A (FRX): Free Stock Analysis Report

SUCAMPO PHARMAC (SCMP): Free Stock Analysis Report

SUPERNUS PHARMA (SUPN): Free Stock Analysis Report

WUXI PHARMATECH (WX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AES , FRX , SCMP , SUPN , WX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

How to Fire Your Adviser
How to Fire Your Adviser            

Stocks

Referenced

Most Active by Volume

75,750,465
  • $16.77 ▲ 0.36%
59,791,764
  • $101.58 ▲ 0.71%
38,720,622
  • $42.59 ▼ 0.28%
37,416,417
  • $46.52 ▼ 0.51%
35,101,793
  • $16.28 ▲ 0.74%
34,987,975
  • $99.53 ▲ 0.15%
33,760,830
  • $3.63 ▲ 0.69%
32,148,671
  • $17.61 ▲ 0.57%
As of 9/17/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com